Beschrijving
Featuring perspectives from Prof John Seymour, including the following topics:
• Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00)
• Venetoclax re-treatment and ongoing trials with acalabrutinib/venetoclax for CLL (6:21)
• First-line treatment with sonrotoclax and zanubrutinib for CLL (13:10)
CME information and select publications
Website: hematologic-oncology.captivate.fm

